开发和验证一个名图,以预测性结肠炎患者对5-氨酸的不反应
Cong Dai1, Zi-Yuan Dong2, Yi-Nuo Wang2
1Gastroenterology, First Hospital of China Medical University, china.
Revista espanola de enfermedades digestivas
|September 14, 2023
概括
在性结肠炎 (UC) 中预测对5-氨基酸 (5-ASA) 的不反应是个性化治疗的关键. 这项研究确定了临床和生化标志物来预测不响应,有助于量身定制的UC疗法.
科学领域:
- 胃肠病学 胃肠病学
- 临床医学 临床医学
- 生物标志物发现发现
背景情况:
- 性结肠炎 (UC) 患者通常对5 - 氨酸 (5-ASA) 治疗没有反应 (NR).
- 预测NR对于开发UC个性化治疗策略至关重要.
- 识别可靠的预测因素可以优化UC患者的治疗结果.
研究的目的:
- 确定临床和生化标志物,预测在UC患者中NR转为5-ASA.
- 开发和验证一个用于预测UC中5-ASANR的诺莫格拉姆模型.
- 增强UC管理的个性化医疗方法.
主要方法:
- 对284名从未接受过治疗的UC患者的回顾性分析,这些患者在2012年至2020年期间被诊断为UC患者.
- 采用多变量逻辑回归来构建5-ASA NR的预测模型.
- 用曲线下的面积 (AUC),校准和决策曲线分析 (DCA) 来评估模型性能.
主要成果:
- 30.3%的UC患者 (86/284) 显示NR到5-ASA.
- 疾病分类,单细胞,血小板分布宽度,血清总胆固醇和α1球蛋白是NR的显著预测因素 (p <0.05).
- 开发的预测模型表现出良好的歧视,AUC为0.852.
结论:
- 在UC患者中开发了一种对5-ASA NR的验证预测模型.
- 疾病分类,单细胞,血小板分布宽度,血清总胆固醇和α1球蛋白是5-ASA NR的有效预测剂.
- 该模型为估计NR风险提供了高临床有效性,支持个性化UC治疗.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
168
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
168
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
354
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
354
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
155
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
155
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
544
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
544
Inflammatory Bowel Disease I: Ulcerative Colitis
213
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
213


